Intra-Cellular Therapies (NASDAQ: ITCI) reported Q2 EPS of ($0.45), $0.14 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $110.8 million versus the consensus estimate of $106.54 million.

Full year 2023 CAPLYTA net product sales guidance increased to $445 to $465 million from the previous range of $430 to $455 million.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.